washington semaglutide & tirzepatide vs for Weight Loss Stopping GLP-1 drugs can quickly

What Is GLP-1, and How Do These Drugs Work

once-daily products need gradual schedule adjustment for time zone changes

A few change how your brain perceives thirst itself

Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events